Experimental stem cell transplant could reduce toxic side effects for fanconi anemia patients
NCT ID NCT04784052
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new way to treat Fanconi Anemia, a rare genetic disorder that causes bone marrow failure. Doctors will give patients donor stem cells that have been specially filtered to remove certain immune cells, along with an experimental antibody called JSP191. The goal is to help the new cells grow and rebuild the blood system with fewer severe side effects than standard chemotherapy. The trial is recruiting 18 participants and will follow them for up to 2 years after the transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FANCONI ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford University
RECRUITINGStanford, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single drink reveal how alcohol triggers oral cancer?
- Gene therapy aims to fix bone marrow failure in fanconi anemia
- New transplant method aims to reduce complications in bone marrow failure patients
- New MRI method could spot oral cancer early in rare disease patients
- New hope for rare cancer: targeted drug afatinib tested in fanconi anemia patients
- New drug combo aims to make bone marrow transplants safer for kids